Dolutegravir monotherapy as a simplified strategy in virologically suppressed HIV-1-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2675-2676

  Moreira, José ^a,b  

^a INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^b Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS;

HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-1; HUMANS;

EID: 85010208110     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw154     Document Type: Letter

References (10)

1. Rokx C, Schurink CAM, Boucher CAB et al. Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients. J Antimicrob Chemother 2016; 71: 1632-6.
2. Gubavu C, Prazuck T, Niang M et al. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother 2016; 71: 1046-50.
3. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
4. Rojas J, Blanco JL, Lonca M et al. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression: a 24-week pilot study. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, 2015. Abstract LBPS4/2. European AIDS Clinical Society, Brussels, Belgium.
5. Katlama C, SouliéC, Blanc C et al. Dolutegravir monotherapy in HIV-infected patients with suppressed HIV viremia. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, 2015. Abstract PS4/4. European AIDS Clinical Society, Brussels, Belgium.
6. Martínez E, Gatell JM. Position of dolutegravir in the treatment of HIV infection. Enferm Infecc Microbiol Clin 2015; 33 Suppl 1: 31-3.
7. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8.
8. Mathis S, Khanlari B, Pulido F et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One 2011; 6: e22003.
9. Erasmus Medical Center. The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial (DOMONO). https://clinicaltrials.gov/ct2/show/NCT02401828.
10. FundacióLluita contra la SIDA. An Open-Label, Randomized, Controlled Clinical Trial to Assess the Safety, Tolerability and Efficacy of Two Dolutegravir-Based Simplification Strategies in HIV-Infected Patients with Prolonged Virological Suppression. https://www.clinicaltrialsregister.eu/ctr-search/search?query=DOLAM.